Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
The Daily Target 2X Long LLY ETF (LLYX) is designed to provide investors with leveraged exposure to the performance of Eli Lilly and Company (LLY), primarily focusing on the biopharmaceutical sector. The ETF aims to deliver twice the daily return of LLY, making it suitable for traders looking to capitalize on short-term price movements in the pharmaceutical market, particularly in the U.S.
LLYX generates revenue through management fees based on the assets under management (AUM). Its leveraged structure allows it to amplify returns, attracting traders looking for high-risk, high-reward opportunities. The ETF's performance is closely tied to the volatility and price movements of Eli Lilly's stock.
Eli Lilly's stock price movements, particularly in response to drug approvals and clinical trial results
Market volatility impacting leveraged ETF performance
Changes in investor sentiment towards biotech stocks
Regulatory developments affecting the pharmaceutical industry
Regulatory changes that could impact drug pricing and market access
Technological disruption in drug development processes
Emergence of alternative investment vehicles that offer similar leveraged exposure
Increased competition from other leveraged ETFs targeting the biotech sector
Potential liquidity risks during market downturns affecting the ETF's ability to maintain its leverage
Market risks associated with high volatility in Eli Lilly's stock
moderate - The performance of LLYX is influenced by the overall health of the pharmaceutical sector, which can be affected by economic cycles and consumer spending on healthcare.
Rising interest rates may increase the cost of capital for leveraged ETFs, potentially impacting investor demand and valuation multiples.
minimal - The ETF is not directly dependent on credit conditions.
momentum - Investors seeking short-term gains through leveraged exposure to Eli Lilly's stock price movements.
high - The ETF is expected to exhibit high volatility due to its leveraged nature and the inherent volatility of biotech stocks.